Dashboard Market News Pricing Contact Us
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
Denali Therapeutics Inc banner

Denali Therapeutics Inc
NASDAQ:DNLI

Watchlist Manager
Denali Therapeutics Inc Logo
Denali Therapeutics Inc
NASDAQ:DNLI
Watchlist
Price: 20.435 USD -3.7%
Market Cap: $3.2B
Write Note Create Alert Ask AI

Wall St Price Targets

DNLI Price Targets Summary
Denali Therapeutics Inc

Wall Street analysts forecast DNLI stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for DNLI is 35.7 USD with a low forecast of 27.27 USD and a high forecast of 44.1 USD.

DNLI Lowest Forecast
Wall Street Target
$27.27
33% Upside
DNLI Average Forecast
Wall Street Target
$35.7
75% Upside
DNLI Highest Forecast
Wall Street Target
$44.1
116% Upside
Lowest Forecast
Price Target
27.27 USD
33% Upside
Average Forecast
Price Target
35.7 USD
75% Upside
Highest Forecast
Price Target
44.1 USD
116% Upside
Denali Therapeutics Inc Competitors:
Price Targets

Revenue
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss

What are analyst estimates?

Gross Profit
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

What are analyst estimates?

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss

What are analyst estimates?

Pre-Tax Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss

What are analyst estimates?

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss

What are analyst estimates?

Continue DNLI Research

Summary
DNLI intrinsic value, competitors valuation, and company profile.
DCF Valuation
DNLI stock valuation using Discount Cash Flow valuation method.
Relative Valuation
DNLI stock valuation using valuation multiples.
Wall St Estimates
DNLI price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
DNLI stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Other Denali Therapeutics Inc listings:
F • EUR
4DN
 SWB • EUR
4DN
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is DNLI's stock price target?
Price Target
35.7 USD

According to Wall Street analysts, the average 1-year price target for DNLI is 35.7 USD with a low forecast of 27.27 USD and a high forecast of 44.1 USD.

Back to Top
ALPHA SPREAD
Follow us
Join 357,600+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.